共 169 条
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
被引:340
作者:
Eaton, John E.
[1
]
Talwalkar, Jayant A.
[1
]
Lazaridis, Konstantinos N.
[1
]
Gores, Gregory J.
[1
]
Lindor, Keith D.
[2
]
机构:
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin Arizona, Div Hepatol, Phoenix, AZ USA
基金:
美国国家卫生研究院;
关键词:
Cholestatic Liver Disease;
Cholangiocarcinoma;
Autoimmune Disease;
Inflammatory Bowel Disease;
DOSE URSODEOXYCHOLIC ACID;
INFLAMMATORY-BOWEL-DISEASE;
IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS;
WIDE ASSOCIATION ANALYSIS;
BILIARY EPITHELIAL-CELLS;
ULCERATIVE-COLITIS;
LIVER-TRANSPLANTATION;
NATURAL-HISTORY;
RISK-FACTORS;
COLORECTAL NEOPLASIA;
D O I:
10.1053/j.gastro.2013.06.052
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
100201 [内科学];
摘要:
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
引用
收藏
页码:521 / 536
页数:16
相关论文

